Payment overview · 2025
General Payments
$4,654.44
180 reported records · 46 companies
Healthcare provider profile · identity verified
Vinicio Hernandez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · ORLANDO, FL · NPI 1154312783
Verified facts
What the public records show
CMS Open Payments records show Vinicio Hernandez, M.D. received $4,654.44 in general payments during 2025 across 180 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 78 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Erleada, Fotivda, Imfinzi, Inqovi, Keytruda, Kisqali, Opdivo, Talzenna, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TALZENNA as an associated drug or biological on 42 records involving 36 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Talzenna by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMFINZI as an associated drug or biological on 14406 records involving 6935 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Imfinzi by this doctor in 2024.
Aveo Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FOTIVDA as an associated drug or biological on 6531 records involving 3922 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fotivda by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 1605 records involving 1197 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Opdivo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Opdivo by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Remicade by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Keytruda by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TALZENNA as an associated drug or biological on 15299 records involving 6607 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Talzenna by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xtandi by this doctor in 2024.
SOBI, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Doptelet as an associated drug or biological on 3467 records involving 2004 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Doptelet by this doctor in 2024.
TAIHO ONCOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INQOVI as an associated drug or biological on 4572 records involving 2852 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Inqovi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $555.85 | 11.9% | 22 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $317.45 | 6.8% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $315.33 | 6.8% | 12 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $226.78 | 4.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $218.35 | 4.7% | 10 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $208.96 | 4.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $207.20 | 4.5% | 9 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $199.97 | 4.3% | 9 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $185.84 | 4.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $173.99 | 3.7% | 8 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $142.99 | 3.1% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $128.91 | 2.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.23 | 2.5% | 5 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $114.90 | 2.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.79 | 2.3% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $104.75 | 2.2% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $95.34 | 2.0% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $94.16 | 2.0% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $93.58 | 2.0% | 4 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $67.16 | 1.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $65.22 | 1.4% | 3 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $63.65 | 1.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.46 | 1.3% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $58.43 | 1.3% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $57.80 | 1.2% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $57.58 | 1.2% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.08 | 1.2% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $54.03 | 1.2% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $39.04 | 0.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.60 | 0.8% | 2 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $35.73 | 0.8% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $33.47 | 0.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $29.48 | 0.6% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $29.17 | 0.6% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $28.56 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.58 | 0.6% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $27.47 | 0.6% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $26.93 | 0.6% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $25.55 | 0.6% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $25.55 | 0.6% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $25.26 | 0.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.10 | 0.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.02 | 0.5% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $22.34 | 0.5% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.54 | 0.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.27 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,498.45 | 176 |
| Education | $155.99 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $317.45 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $290.28 | 11 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $208.96 | 4 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $207.20 | 9 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $185.84 | 5 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $146.48 | 6 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $141.67 | 6 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $139.53 | 7 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $130.03 | 10 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $125.05 | 6 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $113.16 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $105.24 | 4 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $101.79 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $100.79 | 4 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $95.90 | 5 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $95.90 | 5 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $94.30 | 4 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $87.32 | 4 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $81.70 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $81.56 | 4 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $79.41 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $78.84 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $75.31 | 4 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $74.63 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $73.63 | 3 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $67.16 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $65.22 | 3 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $62.46 | 3 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $58.43 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $57.08 | 3 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $55.69 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $54.03 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $54.03 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $52.08 | 2 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $51.10 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $50.71 | 3 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $50.71 | 3 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $48.77 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.65 | 2 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.65 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $35.75 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $35.73 | 1 | 2025 |
Source payment records
|
|||||
| CABLIVI Normalized: cablivi |
Biological | GENZYME CORPORATION | $34.14 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| PROMACTA Normalized: promacta |
Drug | Novartis Pharmaceuticals Corporation | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $31.00 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| Voranigo Normalized: voranigo |
Drug | SERVIER PHARMACEUTICALS LLC | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 | exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FOTIVDA fotivda |
2025 | Fotivda | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMFINZI imfinzi |
2025 | Imfinzi | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INQOVI inqovi |
2025 | Inqovi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 80 | exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPDIVO opdivo |
2025 | Opdivo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TALZENNA talzenna |
2025 | Talzenna | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
67 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | TALZENNA open payments reported associated product |
CMS Open Payments — General Payments 42 supporting records · 36 recipient NPIs · example record 1228896076 |
Talzenna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | IMFINZI open payments reported associated product |
CMS Open Payments — General Payments 14406 supporting records · 6935 recipient NPIs · example record 1206131578 |
Imfinzi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aveo Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | FOTIVDA open payments reported associated product |
CMS Open Payments — General Payments 6531 supporting records · 3922 recipient NPIs · example record 1199896322 |
Fotivda · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 1605 supporting records · 1197 recipient NPIs · example record 1184378433 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | TALZENNA open payments reported associated product |
CMS Open Payments — General Payments 15299 supporting records · 6607 recipient NPIs · example record 1228794230 |
Talzenna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| SOBI, INC Exact reporting entity; no affiliate inference |
2025 | Doptelet open payments reported associated product |
CMS Open Payments — General Payments 3467 supporting records · 2004 recipient NPIs · example record 1240223702 |
Doptelet · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| TAIHO ONCOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | INQOVI open payments reported associated product |
CMS Open Payments — General Payments 4572 supporting records · 2852 recipient NPIs · example record 1211403676 |
Inqovi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Procrit | Epoetin Alfa | 357 | 72 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 169 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 26 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 138 | 38 |
| Anastrozole | Anastrozole | 117 | 41 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 96 | 24 |
| Prednisone | Prednisone | 94 | 29 |
| Tramadol Hcl | Tramadol Hcl | 88 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 18 |
| Keytruda | Pembrolizumab | 80 | 12 |
| Retacrit | Epoetin Alfa-Epbx | 75 | 18 |
| Alprazolam | Alprazolam | 69 | 17 |
| Lupron Depot | Leuprolide Acetate | 67 | 28 |
| Famotidine | Famotidine/Pf | 61 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 15 |
| Hydroxyurea | Hydroxyurea | 56 | 24 |
| Abiraterone Acetate | Abiraterone Acetate | 48 | suppressed |
| Xtandi | Enzalutamide | 44 | suppressed |
| Lenalidomide | Lenalidomide | 42 | suppressed |
| Xgeva | Denosumab | 42 | suppressed |
| Carboplatin | Carboplatin | 41 | 13 |
| Oxaliplatin | Oxaliplatin | 41 | suppressed |
| Eliquis | Apixaban | 39 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Gabapentin | Gabapentin | 37 | suppressed |
| Remicade | Infliximab | 36 | suppressed |
| Imbruvica | Ibrutinib | 33 | suppressed |
| Venclexta | Venetoclax | 33 | suppressed |
| Avastin | Bevacizumab | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 16 |
| Revlimid | Lenalidomide | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 12 |
| Zoledronic Acid | Zoledronic Acid | 27 | suppressed |
| Erleada | Apalutamide | 23 | suppressed |
| Inqovi | Decitabine/Cedazuridine | 23 | suppressed |
| Irinotecan Hcl | Irinotecan Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | 13 |
| Neulasta Onpro | Pegfilgrastim | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | 12 |
| Doptelet | Avatrombopag Maleate | 21 | suppressed |
| Exemestane | Exemestane | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Imfinzi | Durvalumab | 19 | suppressed |
| Paclitaxel | Paclitaxel | 19 | suppressed |
| Udenyca Autoinjector | Pegfilgrastim-Cbqv | 19 | suppressed |
| Alymsys | Bevacizumab-Maly | 18 | suppressed |
| Trelstar | Triptorelin Pamoate | 18 | suppressed |
| Zirabev | Bevacizumab-Bvzr | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Palonosetron Hcl | Palonosetron Hcl | 15 | suppressed |
| Pemetrexed Disodium | Pemetrexed Disodium | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Opdivo | Nivolumab | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Talzenna | Talazoparib Tosylate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Zarxio | Filgrastim-Sndz | 14 | suppressed |
| Abraxane | Paclitaxel Protein-Bound | 13 | suppressed |
| Calquence | Acalabrutinib | 13 | suppressed |
| Fotivda | Tivozanib Hcl | 13 | suppressed |
| Fulvestrant | Fulvestrant | 13 | suppressed |
| Kisqali | Ribociclib Succinate | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Azacitidine | Azacitidine | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Kisqali Femara Co-Pack | Ribociclib Succinate/Letrozole | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Bortezomib | Bortezomib | 11 | suppressed |
| Gazyva | Obinutuzumab | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nivestym | Filgrastim-Aafi | 11 | suppressed |
| Trazimera | Trastuzumab-Qyyp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,654.44 · 180 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, AKEEGA, AYVAKIT, Amtagvi, BALVERSA, BESREMI, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, CABLIVI, CABOMETYX, CARVYKTI, CREON, DANZITEN, DATROWAY, ELIGARD, ELIQUIS, ELREXFIO, ENHERTU, ENJAYMO, ERLEADA, FOTIVDA, Fabhalta, IBRANCE, IMFINZI, INQOVI, JAKAFI, JAYPIRCA, KEYTRUDA, KISQALI, Korlym, LINZESS, LONSURF, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, MONJUVI, NERLYNX, Nubeqa, OJJAARA, OPDIVO, ORGOVYX, Optune Lua (NovoTTF-200T), Orserdu, PADCEV, POTELIGEO, PROMACTA, PROVENGE, PYRUKYND, Quzyttir, REBLOZYL, RETEVMO, ROLVEDON, RUBRACA, RYBREVANT, SCEMBLIX, Stivarga, TALVEY, TALZENNA, TEVIMBRA, TUKYSA, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vitrakvi, Vonjo, Voranigo, Vyloy, WAYRILZ, XPOVIO, XT CDX, XTANDI, ZIIHERA, ZYNYZ, Zoladex | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error